Freeline Therapeutics Holdings PLC is touting data from its Phase I/II clinical trial of FLT180a (vebrinacogene setparvovec) in hemophilia B, showing that virtually none of the patients in the study required Factor IX (FIX) replacement therapy after treatment with the company’s gene therapy.
London-based Freeline plans to move FLT180a into a pivotal Phase IIb/III study, which it will initiate in the second half...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
